Research
Hormonal
Tirzepatid (GIP/GLP-1 agonist) provides superior weight loss and glycemic control compared to Semaglutid in patients with Type 2 Diabetes and Obesity.
If oral medications and lifestyle changes are insufficient, Tirzepatid (10-15mg weekly) is currently the most effective pharmacological option for weight loss and blood sugar control in Type 2 Diabetes, outperforming Semaglutid. Discuss this with your doctor to see if it's appropriate for your specific health profile.
StrongSupportsVERY_HIGH confidence
Letztlich konnte für 10 mg bzw. 15 mg Tirzepatid eine klare Überlegenheit im Vergleich zu Semaglutid sowohl hinsichtlich HbA1c (p = 0,002) als auch Gewichtsreduktion (p < 0,001) gezeigt werden [46].
Why this rating
Based on SURPASS 2, a high-quality phase 3 RCT.
Source
Adipositas und Diabetes mellitus Typ 2 (Update 2026)
Johanna M. Brix et al. · Wiener klinische Wochenschrift · 2026
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →